戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 gressive, with poorer survival compared with recurrent cancer.
2                      Most patients (62%) had recurrent cancer.
3 ng for an elderly parent or for a child with recurrent cancer.
4 and clinical follow-up failed to demonstrate recurrent cancer.
5 is unique population, with a limited risk of recurrent cancer.
6 ts were aged 12 to 39 years with stage IV or recurrent cancer.
7  predict sensitivity to radiation therapy in recurrent cancer.
8 ere twice as likely to be from biochemically recurrent cancers.
9 ells (TIC) is vital to combat advanced-stage recurrent cancers.
10 ) early after transplantation, and 2 (1 with recurrent cancer, 1 with HIV infection) showed HBsAg(+).
11                 Of the 21 newly diagnosed or recurrent cancers, 16 (76%) were detected by FDG PET wit
12 ted to the 9,079 patients with metastatic or recurrent cancer, 8% (n = 710) harbored level 1 or 3B ge
13 c and clinical criteria, suggests that these recurrent cancers actually represent new primary breast
14 thin tumors that are thought to give rise to recurrent cancer after therapy.
15  years, 256 recipients died, 35 (13.7%) from recurrent cancer and 27 (10.5%) from de novo cancer.
16 h resected colorectal cancer are at risk for recurrent cancer and metachronous neoplasms in the colon
17                       Survival is limited by recurrent cancer and organ toxicity.
18 t the concept that AR is fully functional in recurrent cancer and suggest a model by which a poised b
19 ia, COVID-19-related pneumonia, suicide, and recurrent cancer), and at the second interim analysis, o
20 ing tumors in initial staging, management of recurrent cancer, and monitoring of therapy response.
21 ancer early detection, monitoring of MRD and recurrent cancers, and precision selection of molecularl
22 ain and symptom management, and treatment of recurrent cancer are critical competencies of education
23                    However, the search for a recurrent cancer-associated gene alteration that causes
24 Here, we apply this approach to the two most recurrent cancer-associated mutants.
25 teins and nucleosomes are altered by several recurrent cancer-associated mutations in NSD2 and NSD3.
26 e-genome analysis approaches are identifying recurrent cancer-associated somatic alterations in nonco
27 ifications in the TERT promoter; reverting a recurrent cancer-associated TERT promoter mutation in a
28 r, a considerable proportion of women suffer recurrent cancer at distant metastatic sites despite adj
29                                Patients with recurrent cancer bear the burden of these effects along
30  almost always followed by relapse, with the recurrent cancer being resistant to further treatments.
31 adiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from
32 ety outcomes (serious adverse events, new or recurrent cancer, cataract-related adverse events, hemor
33                                              Recurrent cancer-causing fusions of NUP98 produce higher
34 log of gene modules whose expression defines recurrent cancer cell states including 'stress', 'interf
35                               Development of recurrent cancer, de novo cancer, and patient survival w
36         US-guided FNAB of 25 (64%) of the 39 recurrent cancers depicted at US was performed.
37                   Twenty-one (54%) of the 39 recurrent cancers depicted at US were clinically occult.
38 Many eccDNAs are carrying regions related to recurrent cancer driver oncogenes (e.g. CCND1, EGFR and
39 ells, many of which carry regions related to recurrent cancer driver oncogenes (e.g., CCND1, EGFR, an
40                        Finally, we evaluated recurrent cancers from patients whose primary BRCA2-muta
41 ive function and reveals that in PTPRK-RSPO3 recurrent cancer fusions both fusion partners, in fact,
42 e excluded from analysis (58 had potentially recurrent cancer, had previously received treatment, or
43                                              Recurrent cancer has developed in only 1 patient.
44  to 1.9% of patients with newly diagnosed or recurrent cancer in 2015 participating in an interventio
45 on of patients with newly diagnosed or newly recurrent cancer in 2015 participating in an interventio
46 d 50.1% women) with newly diagnosed or newly recurrent cancer in 2015, 12 028 (1.0%) patients had a b
47 gin status is more important than primary or recurrent cancer in predicting long-term outcome.
48 erall, 213 participants with stage 3 or 4 or recurrent cancer in the US Veterans Affairs Palo Alto He
49        However, the disease recurs, and this recurrent cancer is referred to as castration-resistant
50  more than 10 ng/mL and Gleason score of the recurrent cancer more than or equal to 9 are unlikely to
51       Waiting period was not associated with recurrent cancer mortality or all-cause mortality (both
52             We apply easyCLIP to the 33 most recurrent cancer mutations across 28 RBPs, finding incre
53           In contrast, p190A forms harboring recurrent cancer mutations exhibit loss of function in m
54 dscape in cancer genomes, we found that many recurrent cancer mutations previously designated as driv
55 h nodes was associated with an odds ratio of recurrent cancer of 15.50 in the original cohort and an
56  years, 24 pregnant patients with primary or recurrent cancer of the breast were managed by outpatien
57 up (tonsillitis requiring surgery [grade 3]; recurrent cancer of the vulva [grade 4]) and six serious
58 edure in the work-up of all suspected and/or recurrent cancer patients.
59 would help detect an estimated 12 additional recurrent cancers per 1000 women screened, providing an
60                  Patients with metastatic or recurrent cancer receiving germline genotype-directed th
61 ted Rho GTPases are still catching up as the recurrent cancer-related Rho GTPase mutations have only
62 fferentiation significantly increases in the recurrent cancer relative to the primary cancer, a chara
63                 Subgroup analysis of new and recurrent cancers separately, type of immune-modulator t
64 We recommend that patients with advanced and recurrent cancer should be offered early, comprehensive
65 ge of normal and cancer cell types, we found recurrent cancer-specific expression of SP140, driven by
66                          Thus, we describe a recurrent cancer-specific lesion at the level of ubiquit
67  common nidus for the primary cancer and the recurrent cancer that arises after treatment failure.
68 structed breasts depicted 14 (56%) of the 25 recurrent cancers that were detected at US in these pati
69                   Seventeen patients died of recurrent cancer, two died of second primary cancers, an
70                                              Recurrent cancer was determined to be present or absent
71  Significant differences between primary and recurrent cancer were found for transport k(1), influx K
72 cteristic curve for the detection of locally recurrent cancer with MR imaging was 0.49 and 0.51 for r